Crispr Therapeutics Ag (CRSP)
$50.4
+2.52
(+5.26%)▲
Crispr Therapeutics Ag Key Statistics
Market Capitalization | $4.1B |
Revenue TTM | $202.8M |
EBITDA | $-313.1M |
Earnings Per Share (EPS) | $-2.79 |
Profit Margin | -118.13% |
Quarterly Earnings Growth YOY | 0.0% |
Return On Equity TTM | -13.07% |
Crispr Therapeutics Ag share price movements
- $48.89$51.68$50.40
3.0%
Downside
Day's Volatility :5.41%
Upside
2.49%
- $43.42$91.10$50.40
13.85%
Downside
52 Weeks Volatility :52.34%
Upside
44.68%
Crispr Therapeutics Ag Returns
| Period | Crispr Therapeutics Ag | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 2.5% | -6.4% | 0.0% |
6 Months | -8.1% | 0.7% | 0.0% |
1 Year | -29.62% | 10.9% | 0.0% |
3 Years | -36.03% | 10.2% | -21.2% |
Analyst Recommendation on Crispr Therapeutics Ag
- Current
- 1M Ago
- 3M Ago
Analyst Forecast on Crispr Therapeutics Ag
What analysts predicted
Upside of 61.79%
Insights on Crispr Therapeutics Ag
Increasing Revenue
Revenue is up for the last 3 quarters, 504.0K → 602.0K (in $), with an average increase of 8.3% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -126.40M → -85.94M (in $), with an average increase of 47.1% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 54.1% return, outperforming this stock by 82.1%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 33.1% return, outperforming this stock by 69.1%
Crispr Therapeutics Ag Technicals Summary
Sell
Neutral
Buy
Crispr Therapeutics Ag is currently in a neutral trading position according to technical analysis indicators.
Crispr Therapeutics Ag Vs Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Crispr Therapeutics Ag | 1.39% | -8.1% | -29.62% | -36.03% | -26.7% |
 Regeneron Pharmaceuticals, Inc. | -19.29% | -22.98% | -6.09% | 16.5% | 106.01% |
 Biontech Se | 6.62% | 28.33% | 24.67% | -65.3% | 465.36% |
 Alnylam Pharmaceuticals, Inc. | -12.52% | 67.25% | 57.65% | 33.12% | 110.8% |
 Vertex Pharmaceuticals Incorporated | -3.08% | 3.32% | 31.85% | 151.49% | 110.78% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Crispr Therapeutics Ag | 13.4 | NA | -0.21 | -5.14 | -0.13 | -0.1 | NA | 22.73 |
Regeneron Pharmaceuticals, Inc. | 18.25 | 18.25 | 1.1 | 44.91 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.04 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -0.17 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.18 | 0.54 | -0.03 | 0.12 | NA | 60.65 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Crispr Therapeutics Ag | Buy | $4.1B | -26.7% | 13.4 | -118.13% |
Regeneron Pharmaceuticals, Inc. | Buy | $81.1B | 106.01% | 18.25 | 33.61% |
Biontech Se | Buy | $27.1B | 465.36% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $31.6B | 110.8% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $116.1B | 110.78% | 32.84 | -4.51% |
Crispr Therapeutics Ag Institutional Holdings
Capital Research & Mgmt Co - Division 3
9.29%ARK Investment Management LLC
8.79%Nikko Asset Management Americas Inc
3.69%Sumitomo Mitsui Trust Group Inc
3.48%BlackRock Inc
3.26%T. Rowe Price Investment Management,Inc.
3.21%
Company Information about Crispr Therapeutics Ag
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Organization | Crispr Therapeutics Ag |
Employees | 407 |
CEO | Dr. Samarth Kulkarni Ph.D. |
Industry | Health Technology |
